The DOI matches its Crossref record.
Effect of Antidepressant Medication Treatment on Suicidal Ideation and Behavior in a Randomized Trial: An Exploratory Report From the Combining Medications to Enhance Depression Outcomes Study
Abstract
OBJECTIVE: To explore relationships between baseline sociodemographic and clinical features and baseline suicidal ideation, and treatment effects on suicidal ideation and behavior, in depressed outpatients. METHOD: From March 2008 to September 2009, the Combining Medications to Enhance Depression Outcomes study, a single-blind, 7-month randomized trial, enrolled outpatients with nonpsychotic chronic and/or recurrent major depressive disorder (DSM-IV-TR criteria) in primary and psychiatric care (N = 665). Participants received escitalopram plus placebo, bupropion sustained release (SR) plus escitalopram, or venlafaxine extended release (XR) plus mirtazapine. The primary outcome measure for this report is presence of suicidal ideation assessed by the Concise Health Risk Tracking Self-Report, which measures suicidal ideation and behaviors over the last 24 hours. Sociodemographic and clinical features were compared in those with versus without baseline ideation. At 4, 12, and 28 weeks, treatment effects on suicidality were assessed, and unadjusted and adjusted outcomes were compared among those with and without baseline ideation using linear, logistic, ordinal logistic, and negative binomial regression models. RESULTS: Baseline suicidal ideation was associated with greater depressive severity, childhood neglect, childhood abuse, early major depressive disorder onset, greater psychiatric comorbidity, and worse functioning and quality of life. After adjustment for treatment, gender, age at first depressive episode, obsessive-compulsive symptoms, and depressive severity, depressive symptom outcomes did not differ between ideation groups at 12 or 28 weeks or between treatments. Overall, 79% of participants with baseline suicidal ideation had none at week 4, 83% had none at week 12, and 86% had none at week 28. All treatments reduced ideation, with bupropion-SR plus escitalopram the most effective at week 12 (P < .01). In participants without baseline ideation, emergent ideation did not differ between treatments: 2.5% had ideation at 4 weeks, 1.3% had ideation at 12 weeks, and only 1.7% had ideation at 28 weeks. Four patients (all receiving venlafaxine-XR plus mirtazapine) attempted suicide (P = .0162). CONCLUSION: Baseline ideation did not affect depressive symptom outcome. Bupropion-SR plus escitalopram most effectively reduced ideation. Ideation emergence was uncommon. Venlafaxine-XR plus mirtazapine may pose a higher risk of suicide attempts. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00590863.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Medications reduced suicidal behavior in 4/12 adult studies,(55–58) but those effective medications belonged to pharmacologically diverse classes.”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [57]
In the citing paper
“Medications reduced suicidal behavior in 4/12 adult studies,(55–58) but those effective medications belonged to pharmacologically diverse classes.”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [57]
In the citing paper
“More promisingly, antidepressants reduced suicidal ideation in 9/12 studies that reported effects on suicidal ideation.(55, 57, 59–65)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [57]
Citations
Cited by
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060864 · Cited by 655
Suicidal Behaviour in Mood Disorders—Who, When, and Why?
Isometsä, E. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900303 · Cited by 310
Suicidality in obsessive compulsive disorder (OCD): A systematic review and meta-analysis
Angelakis, I., Gooding, P., Tarrier, N., & Panagioti, M. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.03.002 · Cited by 185
Tunnard, C., Rane, L. J., Wooderson, S. C., Markopoulou, K., Poon, L., Fekadu, A., Juruena, M., & Cleare, A. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.037 · Cited by 179
“These findings support previous reports of increased suicidal ideation in abused patients with recurrent MDD (Zisook et al., 2011) and of a preferential association between CEA and suicidal ideation and attempts (Gibb et al.”
BackgroundResultWang, Y.-Y., Jiang, N.-Z., Cheung, E. F. C., Sun, H.-W., & Chan, R. C. K. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.001 · Cited by 138
“In previous studies, the prevalence of SI was highly variable, ranging from 11% to 66% (Morris et al., 2010; Zisook et al., 2011).”
BackgroundDold, M., Bartova, L., Fugger, G., Kautzky, A., Souery, D., Mendlewicz, J., Papadimitriou, G. N., Dikeos, D., Ferentinos, P., Porcelli, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy009 · Cited by 82
“However, most of these surveys assessed suicidality before implementing adequate antidepressant treatment (Zisook et al., 2009, 2011; Morris et al., 2010), whereas our patient sample already received a course of antidepressants before the cross-sectional data collection process and subsequently…”
BackgroundMethod of assessment determines prevalence of suicidal ideation among patients with depression
Vuorilehto, M. S., Valtonen, H. M., Melartin, T. K., Sokero, P., Suominen, K. H., & Isometsä, E. T. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2013.08.005 · Cited by 93
“The reported prevalence estimates of suicidal ideation among MDD patients are, however, highly inconsistent, ranging from 11% to 63% [18,31].”
BackgroundO'Connor, E. J., Gaynes, B. N., Bu, B., Williams, C., & Ep, W. (2013) · Cited by 100
Pharmacological prevention of suicide in patients with major mood disorders
Rihmer, Z., & Gonda, X. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.009 · Cited by 70
Parkinson, J. T., Foley, É. M., Jadon, D. R., & Khandaker, G. M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20970028 · Cited by 54
Interactive effects of N-acetylcysteine and antidepressants
Costa-Campos, L., Herrmann, A. P., Pilz, L. K., Michels, M., Noetzold, G., & Elisabetsky, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.02.008 · Cited by 42
“…and Thase, 2011; Linde et al., 2011; Rocha et al., 2012) and are advocated to improve the prognosis of patients refractory to standard treatment protocols (Bobo et al., 2011; Martín-López et al., 2011; Rojo et al., 2005), as well as those with marked suicidal ideation (Zisook et al., 2011).”
Nobile, B., Olié, É., Dubois, J., Guillaume, S., Gorwood, P. A. P. M., & Courtet, P. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211025697 · Cited by 40
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021004 · Cited by 38
Rational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
“In contrast, combinationsweremore effective in reducing suicidal ideation (Zisook et al., 2011).”
BackgroundPharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30
Self-citationAuditory P3 in antidepressant pharmacotherapy treatment responders, non-responders and controls
Jaworska, N., Somma, E. D., Blondeau, C., Tessier, P., Norris, S., Fusee, W., Smith, D., Blier, P., & Knott, V. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.003 · Cited by 38
“The latter was used due to reported enhanced antidepressant effects with dual drug treatments (Segrave and Nathan, 2005; Zisook et al., 2011).”
Baek, J. H., Heo, J., D, M. F. M., Mischoulon, D., Nierenberg, A. A., Hong, J. P., Roh, S.-W., & Jeon, H. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.006 · Cited by 33
Self-citationChildhood adversity and adulthood major depressive disorder
Zisook, S., Planeta, B. M., Hicks, P. B., Chen, P., Davis, L. L., Villarreal, G., Sapra, M., Johnson, G. R., & Mohamed, S. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.03.008 · Cited by 34
Self-citationUnderstanding suicide: Focusing on its mechanisms through a lithium lens
Malhi, G. S., Das, P., Outhred, T., Irwin, L., Morris, G., Hamilton, A., Lynch, K., & Mannie, Z. N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.036 · Cited by 32
Ge, F., Jiang, J., Wang, Y., Yuan, C., & Zhang, W. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s238286 · Cited by 33
Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., et al. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000218 · Cited by 25
“…research has been the study of medication combinations, such as those tested for the treatment of major depression (eg, Trivedi et al., 2006; Zisook et al., 2011) and a recent study of extendedrelease naltrexone in combination with buprenorphine þ naloxone for cocaine dependence (Mooney et…”
BackgroundSelf-citationSuicide Prevention Interventions and Referral/Follow-Up Services: A Systematic Review
O'Neil, M. E., Peterson, K., Low, A., Carson, S., Denneson, L. M., Haney, E. M., Shiroma, P. R., & Kansagara, D. L. (2012) · Cited by 26
Trombello, J. M., Killian, M., Grannemann, B. D., Rush, A. J., Mayes, T. L., Parsey, R. V., McInnis, M. G., Jha, M. K., Ali, A., McGrath, P. J., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118817156 · Cited by 23
“Baseline suicidal thoughts as assessed through the CHRT-SR are also associated with worse antidepressant treatment outcomes (Zisook et al., 2011).”
MethodSelf-citationOlgiati, P., & Serretti, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000416 · Cited by 20
“Despite this, at least one in five patients who take ADs are not likely to obtain a complete SI remission (Zisook et al., 2011).”
BackgroundMethodInfluentialImplementing Evidence-Based Suicide Prevention Strategies for Greatest Impact
Melhem, N., Moutier, C. Y., & Brent, D. A. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20220078 · Cited by 26
Seo, H., Jung, Y., Jeong, S., Kim, J.-B., Lee, M., Kim, J., Yim, H. W., & Jun, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.002 · Cited by 23
Conséquences de l’inter-relation des systèmes monoaminergiques dans l’activité antidépressive
Tritschler, L., Gaillard, R., Gardier, A. M., David, D. J. P., & Guilloux, J. (2018) · L Encéphale · doi:10.1016/j.encep.2018.05.001 · Cited by 21
“[96] Zisook S, Lesser IM, Lebowitz B, et al.”
BackgroundTrombello, J. M., Kulikova, A., Mayes, T. L., Nandy, K., Carmody, T. J., Bart, G. B., Nunes, E. V., Schmitz, J. M., Kalmin, M. M., SHOPTAW, S. J., et al. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s406909 · Cited by 22
Self-citationFurman, J. L., Soyombo, A. A., Czysz, A. H., Jha, M. K., Carmody, T. J., Mason, B. L., Scherer, P. E., & Trivedi, M. H. (2018) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2018.05.001 · Cited by 21
Self-citationKim, J., Kang, H., Bae, K., Kim, S., Shin, I., Hong, Y. J., Ahn, Y., Jeong, M. H., Kang, H., & Yoon, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.048 · Cited by 14
Villegas, A. C., DuBois, C. M., Celano, C. M., Beale, E. E., Mastromauro, C. A., Stewart, J. G., Auerbach, R. P., Huffman, J. C., & Hoeppner, B. B. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.09.044 · Cited by 12
“…gold-standard for the self-report assessment of suicide risk, it is important to build the evidence base on existing self-report measures to help guide choices about which selfreport scale may be best suited for a specific need (Celano et al., 2017; Iosifescu et al., 2016; Zisook et al., 2011).”
BackgroundYoo, C., Lim, S., Song, K.-H., Woo, D., & Choe, B. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.005 · Cited by 13
A descriptive study of female suicide deaths from 2005 to 2011 in Van city, Turkey
Hekimoğlu, Y., Melez, İ. E., Cantürk, N., Erkol, Z. Z., Dizdar, M. G., Cantürk, G., Melez, D. O., & Kir, Z. M. (2016) · BMC Women s Health · doi:10.1186/s12905-016-0299-1 · Cited by 17
“Suicidal thoughts can be related to serious depression, being abused during childhood, early onset of a major depressive disorder or poor living conditions [35].”
BackgroundOlgiati, P., Fanelli, G., & Serretti, A. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000461 · Cited by 13
“Among them, a pivotal role is played by clinical variables such as depression severity, age at onset and course of depression (Zisook et al., 2011), abuse and violence in childhood (Chou, 2012; Zisook et al.”
BackgroundCharacterization of suicidal depression: A 1 year prospective study
Nobile, B., Olié, É., Dubois, J., Benramdane, M., Guillaume, S., & Courtet, P. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.16 · Cited by 17
The Role of Early Life Stress in HPA Axis and Depression
Juruena, M. F., Cleare, A. J., & Young, A. H. (2017) · Springer eBooks · doi:10.1007/978-981-10-6580-4_5 · Cited by 18
Ren, K. G. M. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000173 · Cited by 7
Olgiati, P., Luca, M., Luca, A., Ferri, R., & Serretti, A. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.06.012 · Cited by 7
Suicidal Behavior Among Elderly Inpatients: its Relation to Functional Disability and Pain
Wahab, S. B., Chua, T. Y., Razali, R., Saher, Z. M., Zamzam, I. H., & Bujang, M. A. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s341768 · Cited by 7
O’Callaghan, E., Mahrer, N. E., Belanger, H. G., Sullivan, S., Lee, C., Gupta, C., & Winsberg, M. E. (2022) · JMIR Formative Research · doi:10.2196/37746 · Cited by 7
“Although antidepressants are a common treatment route, overall, there are conflicting findings regarding whether they reduce SI or suicide, or both [17,36-40].”
BackgroundRizk, H. G., Monaghan, N. P., Shah, S. R., Liu, Y. F., Keith, B. A., Jeong, S. S., & Nguyen, S. A. (2024) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.2241 · Cited by 5
Zhang, H., Wu, Z., Cao, L., Su, Y., Wang, F., Hong, W., Cai, Y., Peng, D., & Fang, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.011 · Cited by 4
Jung, Y., Jun, T., Woo, Y. S., Yim, H. W., Kim, J.-B., Kim, J., & Seo, H. (2023) · Psychiatry Investigation · doi:10.30773/pi.2022.0147 · Cited by 7
Nandy, K., Rush, A. J., Carmody, T. J., Mayes, T. L., & Trivedi, M. H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1014766 · Cited by 4
Self-citationLiang, X., Guo, Y., Zhang, H., Wang, X., Li, D., Liu, Y., Zhang, J., Zhou, L., & Qiu, S. (2024) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2024.100526 · Cited by 5
“Evidence-based depression interventions, such as pharmacotherapy (Henssler et al., 2022; Zisook et al., 2011), Transcranial Magnetic Stimulation (TMS) (Cardenas et al., 2022; Hidalgo-Lopez et al., 2023; Liston et al., 2014), and transcranial Direct Current Stimulation (tDCS) (Chan et al., 2021;…”
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial
Zisook, S., Moutier, C. Y., Rush, A. J., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., Hicks, P. B., WILCOX, J. A., Planeta, B. M., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723003008 · Cited by 3
“This study also confirmed previous reports on the importance of childhood adversity (Tunnard et al., 2014; Zisook et al., 2011) and prolonged grief (Zisook et al., 2021) as risks for adult SI and SA, reinforcing the value of obtaining information about childhood neglect, abuse, trauma, and loss…”
Self-citationAssessing Psychiatric Adverse Effects during Clinical Drug Development
Rudorfer, M. V., & Hillefors, M. (2012) · Pharmaceutical Medicine · doi:10.1007/bf03262382 · Cited by 3
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 3
Treatment of depression with a combination of mirtazapine and venlafaxine - a literature review
Szwedkowicz, A., Miszuda, S., Trojan, S., Fussek-Styga, U., Błaszczyk, A., Kwieciński, J., Basiaga, B., Bednarz, K., Leśniak, M., & Heluszka, J. (2023) · Quality in Sport · doi:10.12775/qs.2023.13.01.004 · Cited by 2
Nandy, K., Goodman, L. C., Mayes, T. L., Ayvaci, E. R., Trombello, J. M., Elmore, J. S., Vasu, S., Emslie, G. J., & Trivedi, M. H. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s529377 · Cited by 1
Self-citationMorris, D. W. (2012) · Clinical Investigation · doi:10.4155/cli.12.142 · Cited by 1
Self-citationAntidepressant Medications and Suicide Risk: What Was the Impact of FDA Warning?
Serafini, G., Solano, P., & Amore, M. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_31 · Cited by 1
Suicidal IdeationPreprint
Goldsmidt, J. (2022) · doi:10.31219/osf.io/kzfj8
Kim, J., & Kang, U. G. (2026) · 신경정신의학 · doi:10.4306/jknpa.2026.65.1.1
TMS-EEG correlate of suicidal ideation in individuals with depression: A multi-site synthesis
Stapper, N., Sun, Y., Poorganji, M., Dhami, P., Hadas, I., Bailey, N. W., Kaewpijit, P., Zomorrodi, R., Kohn, J. N., Fitzgerald, P. B., et al. (2026) · Brain stimulation · doi:10.1016/j.brs.2026.103206
Metadata
- Authors
- Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., Nierenberg, A. A., Fava, M., Luther, J. F., Morris, D. W., & Trivedi, M. H.
- Affiliations
- University of California San Diego (US)
- University of California, Los Angeles (US)
- National University of Singapore (SG)
- University of Pittsburgh (US)
- Harvard University (US)
- Corresponding author
- Zisook, Sidney
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-10-15
- Volume
- 72
- Issue
- 10
- Pages
- 1322-1332
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2094303122
- Cited by
- 55
- References
- 0
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 7 · 2012: 4
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- suicidal ideation, suicidal behavior, major depressive disorder, antidepressant treatment, escitalopram, bupropion, venlafaxine, mirtazapine, child neglect, childhood abuse, depression severity, suicide attempts, treatment response, psychiatric comorbidity, quality of life, primary care depression treatment
- MeSH terms
- Venlafaxine Hydrochloride, Mirtazapine, Adolescent, Adult, Aged, Antidepressive Agents, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Mianserin, Middle Aged, Surveys and Questionnaires, Regression Analysis, Risk Factors, Time Factors, Citalopram, Single-Blind Method, Bupropion, Treatment Outcome, Young Adult, Self Report, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.